Remyelination of neurons using multipotent neural stem cell progeny

Patent Number: 7,166,277

This patent is useful for the cell therapy of diseases associated with demyelination such as multiple sclerosis.

The patent covers the use of neural stem cells expanded ex vivo for the purpose of remyelinating neurons in vitro and in vivo.

Specifically the patent covers use of nestin positive progenitors purified from CNS tissue treated with various differentiation factors such EGF and FGF. The patent teaches that the differentiated cells useful for the practice of the invention are enolase or neurofilament positive and have a glial phenotype that express glial fibrillary acidic protein or galactocerebroside.

View this patent on the USPTO website.